Your Article Summary
See Latest ArticlesPredicting the future of anti-TNF therapy
Arthritis Research & Therapy, 07/01/09
Verweij CL – In the current issue of Arthritis Research & Therapy, Hueber and colleagues report that patients with features of an activated immune status in the peripheral blood compartment are more likely to benefit from anti-TNF treatment. Similar findings were reported for baseline synovial tissue markers associated with responsiveness.
Methods- A multistep proteomics approach to identify a serum protein biomarker set that has predictive value prior to the start of etanercept treatment in RA pts
- Study is based on the premise of a role for differential autoantibody specificities and serum cytokine levels in guiding anti-TNF therapy
- Therapy responsiveness assessed 3 mo after the start of therapy, based on the ACR criteria
- An integrated analysis of a relevant set of 14 autoantibody specificities and a multiplex 12-cytokine Luminex data set
- 93 samples consisting of 3 independent cohorts:
- A US based Autoimmune Biomarkers Collaborative Network (ABCoN) cohort; n=29
- A Swedish cohort (n=43), and
- A Japanese cohort (n=21)
- showed superior differentiation of responders and non-responders
- Autoantibodies were elevated and the trends for all analyzed cytokines, such as TNF, IL-15, MCP-1, and IL-6, revealed higher baseline serum concns in responders
- Subsequent prediction analysis on the full sample set was applied to select an integrated biomarker signature comprising 13 autoantibody specificities and 11 cytokines
- Although the overall prediction does not appear to be that strong, further optimization and preselection of pts on the basis of uniform DMARDs treatment regimens are likely to yield stronger predictive values
Related Articles
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Relevance Score: 71%
Effective anti-tnf-î± therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis
Journal of Rheumatology, 10/09/09
Relevance Score: 70%
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)
Annals of Rheumatic Diseases, 11/13/09
Relevance Score: 69%
Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective French RATIO registry.
Annals of Rheumatic Diseases, 10/22/09
Relevance Score: 69%
Reactivation of hepatitis B viral infection in inactive HBSAg carriers following anti-tumor necrosis factor-alpha therapy
Journal of Rheumatology, 10/05/09
Relevance Score: 69%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Malignancy-associated multicentric reticulohistiocytosis
Rheumatology International, 12/20/09
Ultrasound-guided sacroiliac joint injection in patients with established sacroiliitis: precise IA injection verified by MRI scanning does not predict clinical outcome
Rheumatology, 12/18/09
Unusual central nervous system involvement of rheumatoid arthritis: successful treatment with steroid and azathioprine
Rheumatology International, 12/18/09